TGFB1 and anemia (phenotype): Other inhibitors of TGF‐β signalling include sotatercept, which has shown safety and efficacy against anaemia in non‐transfusion and transfusion‐dependent patients, and elritercept, which is being tested in a Phase 2 study [30, 31].